Elucidation of Epigenetic Landscape in Coronary Artery Disease: A Review on Basic Concept to Personalized Medicine

Abstract

Despite extensive clinical research and management protocols applied in the field of coronary artery diseases (CAD), it still holds the number 1 position in mortality worldwide. This indicates that we need to work on precision medicine to discover the diagnostic, therapeutic, and prognostic targets to improve the outcome of CAD. In precision medicine, epigenetic changes play a vital role in disease onset and progression. Epigenetics is the study of heritable changes that do not affect the alterations of DNA sequence in the genome. It comprises various covalent modifications that occur in DNA or histone proteins affecting the spatial arrangement of the DNA and histones. These multiple modifications include DNA/histone methylation, acetylation, phosphorylation, and SUMOylation. Besides these covalent modifications, non-coding RNAs—viz. miRNA, lncRNA, and circRNA are also involved in epigenetics. Smoking, alcohol, diet, environmental pollutants, obesity, and lifestyle are some of the prime factors affecting epigenetic alterations. Novel molecular techniques such as next-generation sequencing, chromatin immunoprecipitation, and mass spectrometry have been developed to identify important cross points in the epigenetic web in relation to various diseases. The studies regarding exploration of epigenetics, have led researchers to identify multiple diagnostic markers and therapeutic targets that are being used in different disease diagnosis and management. Here in this review, we will discuss various ground-breaking contributions of past and recent studies in the epigenetic field in concert with coronary artery diseases. Future prospects of epigenetics and its implication in CAD personalized medicine will also be discussed in brief.

Keywords

Epigenetics coronary artery disease (CAD)acute myocardial infraction precision medicine therapeutic targets

Introduction

Epigenetics is a term coined from Greek prefix, “epi,” meaning “over,” “external,” or “around,” and the traditional word “genetics” that is inheritance. Hence, epigenetics can be described as the changes affecting heritable phenotype variations without altering the DNA sequence of a genome. Epigenetic change is associated with the covalent modifications in the structural components of chromatin, nitrogenous bases of DNA, and expression of various non-coding RNA species, which decide the expression pattern of genes. They ultimately help in keeping the cell identity, which is censoriously important for normal development and causation of various diseases. During recent 2 decades, epigenetics has seen an extensive surge in the field of precision medicine, and epigenetic changes have been associated with almost all disease states, including malignant and non-malignant, especially lifestyle disorders. They mostly occur due to changes in the microenvironment of cells, which in turn is decided by various modifiable and nonmodifiable factors.¹ Based on these facts, epigenetics plays an inevitable role in disease pathogenesis of coronary artery disease (CAD). Further, exploration of epigenetics underlying various diseases has paved way for the development of novel therapeutic agents. Several drugs targeted to epigenetic factors are under trial.¹

Acute Myocardial Infarction (AMI) is the foremost cause of death worldwide.² The role of epigenetic changes in patients with CAD is comparatively novel concept with interesting findings. Studies have shown that epigenetic alterations significantly contribute to the development of acute myocardial infarction. Endothelial dysfunction, imbalance in cholesterol metabolism, and atherosclerotic plaques are the primary pathophysiological modification leading to CAD. These changes, along with the risk factors of CAD-like obesity, diabetes mellitus (DM), hypertension, and insulin resistance, are interrelated to environmental risk factors associated to increased rate of CAD.³ The development of atherosclerotic plaque follows epigenetic changes of vascular smooth muscle cells (VSMCs), endothelial cells (ECs), and macrophages. Inflammation, cholesterol metabolism, and homocysteine homeostasis are associated with the development of atherosclerotic plaque, the main pathologic change resulting in CAD.⁴

A number of reports regarding influence of epigenetics on CAD are being added to the literature on an exponential rate, paving the way to explore the underlying epigenetic mechanisms of the disease. In this review, we will discuss the latest discoveries related to epigenetic modifications in fetal and adult stages that contribute to the CAD development and its progression. Also, how the environment coordinates with epigenetics of an individual towards the initiation and development of CAD, as well as the role of epigenetics in personalized medicine will also be discussed to provide a comprehensive view to readers.

Pathophysiology of CAD

Atherosclerosis is a chronic inflammatory condition which is characterized by thickening of vascular wall leading to luminal obstruction.⁵ It is the basic pathogenic lesion in vaso-occlusive conditions of different organ systems like coronary artery disease and peripheral artery disease. Atherosclerotic plaque is composed of an accumulation of lipids, T lymphocytes, macrophages and fibrous tissues in arterial walls. This theory is known as the “response to injury” hypothesis, implicating endothelial disorder as the primary step in the cascade of different pathological stages of this chronic inflammatory condition, which precedes any structural alterations in the arterial wall occur.⁶ The result of the process is the endorsed expression of intercellular and vascular cell adhesion molecules due to low-density lipoprotein (LDL) cholesterol oxidation in subendothelial space, which ultimately leads to monocyte adhesion/ migration to the subendothelial area. In the intima monocytes differentiate into macrophage which engulf oxidized LDL via scavenger receptor promoting foam cell formation and exhibit proinflammatory functions by secreting cytokines—viz. interleukins and tumor necrosis factor.

The end step of this process is the formation of atherosclerotic lesion I (fatty streak). Atherosclerotic build up results in plaque formation, vascular remodeling, acute and/or chronic luminal obstruction, abnormalities of blood flow and diminished oxygen/ nutrients supply to myocardium. By impairing or obstructing normal coronary blood flow, atherosclerotic build up causes myocardial ischemia.⁷ In this review we will discuss the epigenetics modifications played a significant role in the pathogenesis of CAD.

Risk factors for CAD have been classified into demographic, biochemical parameters, lifestyle and genetic factors. Demographic factors include advancing age and male sex, biochemical parameters include variables such as raised cholesterol levels, lifestyle factors include sedentary working habits, high levels of stress and depression, unbalanced dietary habits, socioeconomic status and alcohol or smoking/tobacco abuse and genetic factors include positive family history for CAD and inherited disorders of lipid metabolism.⁵

In demographic factor, age play a pivotal role in development of CAD.^8,9 A study by Ravi et al demonstrated that increasing age is an independent risk factor for CAD.¹⁰ Considering gender, men of all ages have higher mortality from CAD than women before menopause.¹¹ Several studies marked that; the incidence of CAD is similar in post-menopausal woman in age matched men.^12-14 Several studies have reported high risk lifestyle choices are associated to epigenetic alterations such as histone modifications and DNA methylations are strongly associated with obesity leading to coronary artery disease.¹⁵ A recent study indicated that different candidate gene methylations are associated to lipid metabolism and inflammation in subjects with obesity.¹⁶ Also, a recently published study demonstrates that tobacco smoking is associated with DNA methylation at several loci of atherosclerotic carotid lesions.¹⁷ Moreover, a study by Rebecca et al. reveals that specific DNA methylation patterns have been found in tobacco smoking CAD patients.¹⁸ Those who smoke may have a vulnerability to illness with a heritable (genetic) component for CAD, T2DM, or hypertension, yet once the patient quits smoking, the likelihood of having/developing the disease phenotype starts to remit.¹⁹ Also, Lohoff et al revealed that inducement of chronic alcohol modifies PCSK9 methylation leads to impairment of lipid metabolism and CAD.²⁰ Epidemiological studies propose that early life, mainly prenatal, environmental exposure can induce metabolic and physiological changes in fetus by modifying epigenetic profiles leading to predisposition of multiple chronic diseases such as diabetes, obesity, cardiovascular event, and cancer.²¹ Accumulating reports from numerous studies suggest that epigenetics might be one of the unique molecular mechanisms with different contributing factors like fetal programming, environmental stimulus, and childhood phenotype. Owing to the reversible nature of these factors, epigenetic modifications are becoming an attractive therapeutic agent.²²

Inception of epigenetics in response to environmental variances

Intrauterine exposure

External stress modulates cellular and tissue level maturity. Severity varies depending time of exposure within narrow window period of genetic variation or specific organogenesis. Intrauterine development is highly sensitive for modifications in response to environmental stress in order to fine tune genotypic and phonotypic traits. This high level of developmental plasticity is not only adaptive but also may result in maladaptive change paving way for pathological processes.^21,23 Epigenetic modulations can be inheritable through subsequent generations resulting in transgenerational epigenetic inheritance. Available micro milieu imparts most drastic effect on epigenetic status and modulation of transcriptome in early few weeks of pregnancy.²² Diet, pathological conditions like hypertension, DM, smoking, chemical pollutants, and psychological stress have been proven to have important role in determining epigenetic landscape for future disease processes (Figure 1)^24,25.

Figure 1.

Increased risk of developing CAD with the effect of environmental inducements through intrauterine and after birth exposure.

Exposure after birth

Exposure to environmental pollution has been associated with cardiovascular risk factors. It is an established fact that smoking is the strongest independent risk predictor for premature coronary heart disease; moreover, second-hand smoke (SHS) has been characterized as an environmental pollutant contributing approximately to 80% death due to CAD and only <5% death from lung cancer.²⁶ This suggests coronary atherosclerotic tissues are susceptible to environmental chemical pollutants. A meta-analysis of genome-wide DNA methylation conducted by Roby Joehanes et al in 2017 revealed that changes in DNA methylation sites are associated with cigarette smoking highlighting thousands of differentially methylated CpGs.²⁷ Dietary influence on CAD has been studied widely suggesting both Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diet, that is filled with vegetables, fruit, and nuts are associated with decreased risk of AMI and improved effects on blood pressure, lipid profile, inflammation, endothelial function, and thrombosis.²⁸ Specific research to elucidate the effect of dietary determinants on CAD risk modifying epigenetic modifications is lacking, although literature suggests diet may influence factors such as DNA hyper and hypomethylation.²⁹ Future research strategies might prove to be a worthwhile investment of resources to describe diet—epigenetics interactions leading to atherosclerotic disorders.

Another important factor resulting in epigenetic aberrations includes a sedentary lifestyle, which possesses a significant role in deciding the pattern of expression of different genes. This is achieved through changes in the microenvironment of chromatin affecting its spatial states; hetero/euchromatin ultimately changes the ability of transcription machinery to DNA accessibility despite the absence of DNA alterations.³⁰ The epigenetic changes lead to gain and loss of function, as observed in animal models.^31-35 In this article, we aimed to review Epigenetic factors, including DNA methylation, histone alteration, and noncoding RNA control, as a risk factor of CAD by altering the relationship between genes and the environment.

Epigenetic changes can present as:

(1) Covalent modifications including methylation, acetylation, phosphorylation, SUMOylating, ubiquitination.

(2) Non-coding RNAs—viz. miRNA, lncRNA, and circRNA (Figure 2).

Figure 2.

Environmental factors affecting epigenetic upbringing such as covalent modifications and different expression of non-coding RNAs leading to the development of Coronary Artery Disease over the years.

Covalent Modifications

Methylation of DNA

Amongst the covalent modifications, DNA methylation, which is a pre-transcriptional modification, has been extensively studied. It is the major epigenetic modification in mammals. DNA methylation shows a covalent transfer at CpG dinucleotide regions where methyl group (–CH3) attached to the fifth carbon of cytosine base. This process is catalyzed by particular enzymes called DNA methyltransferases (DNMTs).³⁶ DNA methylation is involved in multiple factors such as basic biological activities of the cell, gene expression, aging, malignancies and non-malignancies such as CAD.^36,37 It is estimated that a total of 70% to 80% of CpG dinucleotides exist in a state of methylation in the human genome’s dinucleotides may cluster as CpG islands and serve as functional units to regulate gene expression by deciding the binding of transcription factors.³⁸ The frequency of CpG dinucleotide is higher in promoter regions as compared to intronic and exonic region.³⁹ Hypermethylation of promoter regions in somatic cells inhibits their activity. On the other hand, promoters with strong activation are largely unmethylated.⁴⁰ There are 3 angles that are being used to study the association between DNA methylation and CAD, as shown in Figure 3.

Figure 3.

Different approaches to study the association between DNA methylation and CAD.

Role of DNA methylation in CAD

Lipid metabolism plays a pivotal role in atherosclerosis. It is affected by genetic and environmental factors both. Hypermethylation of certain genes like insulin like growth factor-2 (IGF2) and leptin genes is associated with risk factors of CAD, namely obesity and insulin receptor (IR).^41,42 Hypermethylation of ATP Binding Cassette Subfamily G Member (ABCG1)⁴³ and hypomethylation of Carnitine palmitoyltransferase 1A (CPTIA)⁴⁴ has been shown to be associated with postprandial lipemia. Differential patterns of methylation are observed in genes involved in the pathogenesis of CAD and lipid homeostasis.⁴⁵

Global DNA methylation

The environmental and lifestyle factors which contribute to the development of CAD involve the epigenetic changes in the genome. Epigenetic modifications start in utero itself, which is a vulnerable period that can program the individual for risk of disease in adulthood.⁴⁶ Later the early and midlife environmental exposures to smoke, environmental contaminants and pollution lead to methylation of DNA, laying the foundation of non-genetic mechanisms by which CAD might develop and manifest later in life. Also, a protein-restricted diet and diet deficient in vitamin B12, folate, methionine in pregnant animals, and a low-fat flavonoid-rich diet affects the methylation patterns in specific genes contributing to atherogenesis. Smoking, environmental toxins, and pollution contribute to atherogenesis and have been observed to alter the methylation in specific genes.^47-49

The various reports have elucidated that modifications in DNA methylation sites contribute to the regulation of different biological processes, including coronary atherosclerosis, hypertension, and inflammation, that play a significant role in the development of CAD.^50-52 For instance, mice with hypomethylated DNA had overexpression of inflammatory markers, which leads to the formation of aortic fatty streaks.⁵³ In CAD prone mice lacking ApoE, modified DNA methylation sites are found in both blood leukocytes and aorta before the formation of vascular lesions.⁵⁴ These modifications contribute to inflammation and atherosclerotic plaque.

Different studies have reported that both hypomethylation and hypermethylation status in CAD patients. Although global hypomethylation has been reported in DNA from atherosclerotic tissues,^25,55,56 CAD associated genes have been found to be hypermethylated in promoter regions more commonly⁵¹ (Table 1). These differences could either be due to the presence of epigenetically/genetically non-identical cells in atherosclerotic tissue. Moreover, different methylation patterns may be associated with heterogeneous cell types of an individual’s tissue. While hypermethylation looks to be a greater contributing factor for CAD development, compared to hypomethylation, emerging single-cell sequencing technologies could overcome these discrepancies in the future.

Table 1.

Global DNA methylation pattern in CAD.

References	Sample source and sample size (n)	Methods	Global DNA methylation status
Zaina et al⁵⁷	Post mortem donor:	Bisulfite treatment and DNA methylation microarray	Hypermethylation
	Human atherosclerotic tissue (n = 1)
	Human normal aortic tissue. (n = 1)
Nazarenko et al⁵⁸	Human atherosclerotic tissue obtained from right coronary arteries and carotid in an advanced stage (n = 12)	The Illumina HumanMethylation27 BeadChip microarrays	Hypomethylation
	Human atherosclerotic tissue from resistant internal mammary arteries of men (n = 8)
	Selected CpG sites quantified in vascular tissue (n = 80)	Bisulfite pyrosequencing
del Pilar Valencia-Morales et al⁵⁹	Human atherosclerotic aortic tissue samples ranging from histological grade III to VIA (n = 15)	DNA methylation microarray	Hypermethylation
del Pilar Valencia-Morales et al⁵⁹	Human normal aortic tissue samples (n = 15)	DNA methylation microarray	Hypermethylation
Hiltunen et al⁶⁰	Human normal arterial tissue samples (n = 3)	HPLC bisulfite sequencing	Hypomethylation
	Tissue samples from fatty streaks (n = 23)
	Tissue samples from advanced lesions (n = 29)
Sharma et al⁶¹	Angiographically confirmed CAD patients (n = 18)	12 k human CpG Island microarray	Hypermethylated
Sharma et al⁶¹	Healthy control (n = 18)	12 k human CpG Island microarray	Hypermethylated
Sharma et al⁶²	Peripheral lymphocyte of angiographically confirmed CAD (n = 137)	Methylation-sensitive restriction enzymes (MSRE)	Hypermethylated
Sharma et al⁶²	Control (n = 150)	Methylation-sensitive restriction enzymes (MSRE)	Hypermethylated

Candidate gene DNA methylation

An alternative way to investigate the methylation patterns is to analyze methylation at CpG dinucleotides of the targeted genes. Some reports from current studies associated to the pathophysiology of atherogenesis are compiled and depicted in Table 2. Modifications in the methylation status of a specific gene of interest can affect the functional pathways involved in atherogenesis such as LDL metabolism, lipid homeostasis, cholesterol biosynthesis, homocysteine metabolism, endothelial dysfunction and, inflammation.

Table 2.

Candidate gene DNA methylation status in CAD.

Reference	Candidate gene	Technique	Sample source and sample size (n)	Methylation pattern	Methylation site	Expression pattern
Zhu et al⁶³	MTCT3	Bisulfite sequencing	Aortas of heart donors	Hypermethylation	Exon2	Downregulation
			Aortic tissue (n = 23)
			Normal aortic tissue (n = 10)
Huang et al⁶⁴	ES α	Nested methylation specific polymerase chain reaction (MS PCR)	Human Atherosclerosis blood (n = 54)	Hypermethylation	Promoter	Not measured
Huang et al⁶⁴	ES α		Healthy control blood (n = 24)	Hypermethylation	Promoter	Not measured
Kim et al⁶⁵	Esβ	Methylation-specific PCR (MS PCR)	Human atherosclerotic tissue (n = 2)	Hypermethylation	Promoter	Downregulation
Kim et al⁶⁵	Esβ	Methylation-specific PCR (MS PCR)	Human normal tissue (n = 2)	Hypermethylation	Promoter	Downregulation
Zuo et al⁶⁶	IL6	Bisulfite treatment and pyrosequencing	CHD blood sample (n = 212)	Hypomethylation	Promoter	Not measured
Zuo et al⁶⁶	IL6	Bisulfite treatment and pyrosequencing	CHD free blood sample (n = 218)	Hypomethylation	Promoter	Not measured
Bakshi et al⁶⁷	STAT1, IL12b, MHC2, iNOS, JAK1, JAK2	Methylation specific high resolution melting curve (MS-HRM) assay	PBMCs of CAD patients (n = 25)	Hypomethylation	Promoter	Not measured
Bakshi et al⁶⁷	STAT1, IL12b, MHC2, iNOS, JAK1, JAK2		Control (n = 25)	Hypomethylation	Promoter	Not measured
Ghosh et al⁶⁸	GLANT2, HMGCR, CGK eNOS3	Targeted bisulfite sequencing	Healthy subjects (n = 42)	Hypermethylated	Prompter
Ghosh et al⁶⁸	LDLR	Targeted bisulfite sequencing	CAD patients (n = 33)	Hypomethylated	Prompter

Therefore, exploring candidate gene methylation pattern in CAD using novel cutting-edge techniques help us to confirm the contribution of new genes after global methylation studies. This will open up a new therapeutic window for targeted therapies and prognostic markers after validation.

Epigenome-wide association studies

Different epigenome-wide association studies (EWAS) have been conducted in coronary atherosclerosis linked to DNA methylation at the CpG site to elucidate its role at the molecular level.^69,70 The results of recent studies are shown in Table 3. EWAS study reveals that patients with CAD have a different pattern of DNA methylation sites at several genomic loci.

Table 3.

Epigenome-wide association studies.

Reference	Sample source and sample size (n)	Methods	Ethnicity	Methylation status
Reference	Sample source and sample size (n)	Methods	Ethnicity	Total CpG sites	Hypomethylation	Hypermethylation
Castillo-Díaz et al⁷³	Human atherosclerotic tissue (n = 45)	Microarray	Hong Kong	10367 CpG sites	NA	151 CpGs in the control site
Castillo-Díaz et al⁷³	Human non atherosclerotic tissue (n = 16)	Microarray	Hong Kong	10367 CpG sites	NA	141 sites were partially methylated
Yamada et al⁷⁴	Post mortem aortic tissue (n = 64)	DNA methylation-specific microarray (Infinium Methylation EPIC Bead Chip, Illumina, Inc.)	Japan	853307CpG sites.2679 CpGs were significantly associated	407 CpGs	2272 CpGs
Shen et al⁷⁵	Blood sample of atherosclerotic stroke patients (n = 12)	Illumina Infinium Human Methylation 450K Bead chip	China	482360 CpG site	438 CpGs	574 CpGs
Shen et al⁷⁵	Blood samples from matched control (n = 12)	Illumina Infinium Human Methylation 450K Bead chip	China	482360 CpG site	438 CpGs	574 CpGs
Nakatochi et al⁶⁹	Blood sample of MI patients (n = 192)	Illumina Infinium Human Methylation 450 K Bead chip	Japan	348595 CpG site	Not studied	Not studied
Nakatochi et al⁶⁹	Blood sample matched control (n = 192)	Illumina Infinium Human Methylation 450 K Bead chip	Japan	348595 CpG site	Not studied	Not studied
Rask-Andersen et al⁷⁰	Blood sample (n = 729)	Illumina Infinium Human Methylation 450 K Bead chip	Sweden	470789 Sites	Not studied	Not studied
Banerjee et al⁷⁶	Angiographically positive male (n = 6)	Illumina Infinium Human Methylation 450 K Bead chip	India	429DMRs	222	207
Banerjee et al⁷⁶	Angiographically negative male (n = 6)	Illumina Infinium Human Methylation 450 K Bead chip	India	429DMRs	222	207

Some investigators have found different methylated CpG sites in a specific gene; while others have observed a CpG island with increased methylation sites.⁷¹ Correspondingly, EWAS scrutinize gene-specific DNA methylation. Gradually, EWAS has substituted the candidate gene method as it is useful to find novel CpG sites linked to disease phenotype.⁷² Although a large proportion of previous EWAS confirmed their results on replication, the smaller sample size in these studies asks for further validation of the obtained results. A total of 84 translating loci with varied amounts of methylation were identified in at least more than 1 EWAS which suggests an investigation of epigenetic regulation of the identified genes in coronary atherosclerotic statuses. The results revealed a group of genes highlighting the significance of various conditions including carbohydrate and lipid metabolism along with obesity, inflammation and many others in CAD.⁷¹ Still, these patterns are mostly inconclusive, warranting future research with a larger sample cohort.

Histone modifications

Histones are alkaline proteins around which DNA is wrapped to form bead-like structures called nucleosomes. Histones are characterized by 5 families: H1/H5, H2A, H2B, H3, and H4.⁷⁷ Histones are a fundamental unit of chromatin.⁷⁸ These proteins are extremely unstable. They modify rapidly in response to any external signal. Histone molecules undergo several post-translational modifications due to different molecular mechanism at chromatin and amino acid levels.⁷⁹ Amongst the multiple changes, histone acetylation, methylation, and phosphorylation are found to be associated with transcription regulation and gene expression. Post-translational modifications of histones can interfere with chromatin structure, organization, and function, which in turn alter mechanisms such as gene expression, DNA repair, DNA damage, and ultimately affecting the proliferative capacity of the cells.⁸⁰ Moreover, histone methylation and demethylation have been studied in coronary atherosclerosis widely.⁸¹

Histone methylation and demethylation

Histone methylation is directly linked to activation or inactivation of a specific gene. Owing to the modified segment of histone a gene decides whether to activate/inactivate.⁸² In 1960s, methylation pattern on histone was first identified. The methylation enzyme was unknown until the event of the lysine methyltransferase (KMT) family was found.⁸³ Histone methylation was considered to be the ultimate stone post-translational modification until the detection of first histone lysine de-methylase (KDM).^84-86 Methylation of histone can occur both in arginine and lysine residues. At histone H3 and H4, the following methylation residues are documented: K4, K9, K27, K36, K79, and K20. Methylation of lysine residues can be found in multiple degrees, such as mono(me1)-, di (me2), or trimethyl (me3) groups.

Histone-lysine methyltransferase acts as a catalyst. It transfers a methyl group from S-adenosylmethionine (SAM) to amino groups on lysine residues to histone tails.⁸⁷

Discovery of lysine demethylating enzymes altered the primitive concept of irreversible and stable nature of histone methylation. Now, things are changed, and 2 critical classes of histone-lysine dimethyl enzymes are known. It is reported that flavin adenosine dinucleotide is being used as a cofactor of lysine-specific de-methylases (LSDs). The most studied LSD includeLSD1, which interacts with protein complexes like CoREST (resting corepressor) and other protein complexes catalyzing reversible methylation of H3K4 and H3K9.^85,88 A recent study has shown that JmjC domain-containing proteins are the largest class of histone de-methylases. They act as a catalyst and take part in histone demethylation by using Fe (II) and alpha-ketoglutarate as a cofactor.⁸⁶ Though arginine demethylating enzymes have been studied extensively, still histone lysine demethylation is found to possess a predominant role in the process of gene transcription.⁸⁷ A number of studies have been widely demonstrated the association between histone methylation and atherosclerotic plaque.^88-90 In 2015, Greibel et al. established that H3K9me2 and H3K27me2 were significantly reduced in atherosclerotic plaque. They also found the H3K4me2 level in the atherosclerotic and healthy carotid artery. Simultaneously, immunohistochemistry results showed elevation of H3K4me2 in VSMCs, while H3K9me2 showed reduction. Likewise, H3K9me2 and H3k27me2 both the levels are reduced in inflammatory cells. Interestingly, the expression of the corresponding histone methyltransferases MLL2 and G9a was augmented in an advanced stage of atherosclerosis as compared to its early stage.⁸⁸ Further, in 2015, Wierda et al observed that the global H3K27me3 level was less expressed in vessels with advanced atherosclerotic plaques. Though, this result does not affect the equivalent histone methyltransferase (EZH2) or de-methylase JMJD3, suggesting H3K9 and H3K27 demethylation were significantly associated with atherosclerotic plaque formation.⁸⁹

Histone methylation of H3K4 is linked with the development and progression of coronary atherosclerosis.⁹¹ However, increased demethylation of H3K27 has been detected in the advanced stage of CAD.⁸⁹

The significant impact of histone proteins is due to their intimate association with DNA, which makes them vital in a variety of regulatory processes. Hence histones are the main components that are exceptionally important in the onset and progression of CAD phenotype. However, their exact role is substantially diverse, and any specific pattern is yet to be established.

Acetylation of histone tails

Histone acetylation at lysine residues was discovered approximately 50 years ago.^93,94 After the discovery of histone acetylation, researchers have identified some enzymes that catalyze reversible acetylation. The protein lysine acetyltransferase (KATs), initially known as histone acetyltransferase (HATs) and histone deacetylases (HDACs), also act on many non-histone substrates. Most acetylation substrates are localized in the nucleus and act as transcription factors and coregulators.^95,96 Various studies have established a significant role of acetylation in gene expression and regulation of chromatin structure.^97,98 Furthermore, acetylation and deacetylation are the fundamental natures of histone modifications that play a major role in many biological processes.⁹⁹ Overall, transcriptional activation induced by HATs results from an addition of acetyl group. In contrast, the transcription inhibition induced by HDACs results from removal of the acetyl group from H3 and H4 in the N-terminal tails at lysine residues.⁶⁰ In 2016, Greibel et al. revealed that H3K4 methylation and H3K9 acetylation were significantly correlated with the severity of coronary atherosclerosis.⁹² Different expression patterns of class II histone de-acetylase releases acetyl group from histone molecule and found to be associated with coronary atherosclerosis. Also, HDAC₂ is less expressed due to oxidized low-density lipoprotein (ex-LDL), which shows increased oxidative stress. Overexpression HDAC2 cDNA in human aortic endothelial cell downregulate Arg2 expression, which in turn block the oxidized low-density lipoprotein mediated vascular dysfunction.¹⁰⁰

HATs and HDACs are the primary enzymes for the regulation of lysine acetylation levels, suggesting these can be used as a therapeutic target in the management of coronary atherosclerosis.

Phosphorylation

Phosphorylation of histone proteins occurs in the hydroxyl groups of serine, threonine, and tyrosine residues. Kinases act as a catalyst and take part in the addition of phosphate group from ATP, whereas phosphatases catalyze the removal of the phosphate group. The phosphate group converses a negative charge in phosphorylation, which is associated with the chromatin model and leads to gene transcription.¹⁰¹ However, the calcium/calmodulin-dependent protein kinase II δ (CAMII δ) exhibit a significant role in the pathogenesis of cardiac hypertrophy.⁹⁹ It is reported that chromatin remodeling is facilitated by nuclear CAMII δ through phosphorylation of H3Ser10, which endorse gene transcription and leads to coronary artery diseases.^102,103

SUMOylation and ubiquitination

SUMOylation and ubiquitination are important mechanisms responsible for histone post-translational modification that comprises of addition or removal of large bulky groups.¹⁰⁴ These 2 mechanisms show their resemblances in terms of 3D structures of SUMO and ubiquitin proteins.¹⁰⁵ SUMOylation regulates miscellaneous cellular processes with cell cycle, transcription, protein stability, DNA replication/repair, signal transduction, apoptosis.¹⁰⁶ SUMOylation is essential for cardiac function under pathological and physiological condition.¹⁰⁷ It has been shown that failing heart encourages SUMO2/3 conjugation. Additionally, an elevated level of SUMO2/3-dependent modification has been observed to effect in congestive heart disease (CHD) such as cardiac hypertrophy by promoting cardiac cell death.¹⁰⁸ Similarly, the role of SUMOylation in cardiac protein degradation has also been established.¹⁰⁹ In contradiction, over-expression of SENP5, SUMO2/3-specific deconjugation enzyme has been detected to result in dilated cardiomyopathy or cardiac failure.¹¹⁰ The role of SUMOylation and ubiquitination has not been specifically explored in atherosclerotic conditions, in spite of the fact that these may prove to be attractive candidates to elucidate the molecular mechanisms of post-AMI cardiac remodeling. This could create a future area of research.

Non-coding RNAs

NIH conducted “ENCODE” project reported that only 3% of the human genome is translated to proteins, where 86% is transcribed to non-coding RNAs (nc RNAs).^111,112 In the year 1950, worldwide published data demonstrated that there was no association between the genome and the developmental biology of organisms, and the non-coding genome was considered as a garbage gene.^113-115

However, recent studies revealed the significant role of non-coding genome in the mechanism of gene expression, regulation followed by protein expression, and also in the pathogenesis of many diseases, both malignant and non-malignant, including coronary atherosclerosis.¹¹⁶ nc RNAs are transcribed from DNA and perform important regulatory and structural functions.¹¹⁷ Mainly, nc RNAs are divided into 2 classes (a) small ncRNAs containing <200 nucleotides and (b) long nc RNAs with a length more than 200 nucleotides. Nowadays, non-coding RNAs are being implicated in the pathogenesis of coronary atherosclerosis and hence act as important biomarkers of cardiovascular injury.¹¹⁸

miRNAs

Discovery of micro RNAs (miRNAs) is an innovative domain in translational research. These miRNAs can instantly regulate expression of different genes through various molecular mechanism. The nucleotide sequence of miRNAs is extremely preserved across, act as a modulator of gene expression and gene regulation.¹¹⁹ Till date, approximately 2500 miRNAs have been discovered in the human genome and these are responsible for the regulation of 62% of human genes.¹²⁰ The role of miRNAs in coronary artery disease has been widely studied over the years. Thus, miRNAs are found to be major regulator in cellular gene expression for the initiation and progression of CAD.¹²¹ List of reported studies where miRNA played a substantial role in CAD are depicted in Table 4. Also, literature supports that miRNAs such as miRNA1 and miRNA133a can be used as better diagnostic and prognostic biomarkers for AMI in comparison with cardiac troponins.¹³⁸

Table 4.

List of miRNA associated with Coronary artery disease.

References	miRNAs	Sample source	Findings
Fichtlscherer et al¹²⁴	miRNA155, miRNA145, miRNA17a and miRNA92a, miRNA133a and miRNA208a	Human plasma	Reduced in patients with CAD compared healthy control
Fichtlscherer et al¹²⁴		Human plasma	Overexpressed in patients with CAD compared to healthy control
Vindis et al¹²⁵	miRNA155, miRNA145	Human plasma	Significantly under-expressed in stable coronary atherosclerosis patients as compared to healthy subjects
Wang et al¹²⁶	miRNA133	Human plasma	Significantly higher in AMI patients as compared to control group
Wang et al¹²⁶	miRNA133	Human plasma	Positively correlated with the severities of the coronary artery stenosis
Liu et al¹²⁷	miRNA370 and miRNA208a	Human plasma	Both the miRNAs are significantly higher in CAD patients as compared to control
			miRNA208a differentially expressed in heart muscle
			miRNA370 associated with lipid metabolism
Zhang et al¹²⁸	miRNA208a	Human plasma	Associated with the severity of CAD
Wang et al¹²⁹	miRNA31	Human plasma	Higher in the CAD patients with restenosis as compared to those without restenosis
Sayed et al¹³⁰	miR208,iR499, miR133 and miR1	Human plasma	Upregulated in AMI patients compared to healthy control
Sondermeijer et al¹³¹	miR340, miR451, miR624	Human platelet	Upregulated in CAD patients compared to healthy control
Corsten et al¹³²	miRNA208a	Human plasma	1550 fold higher in AMI patients as compared to healthy subjects
Xin et al¹³³	miRNA499-5p	Human plasma	10 fold higher in AMI patients as compared to healthy subjects
Adachi et al¹³⁴	miRNA499	Human plasma	It has higher sensitivity compared to troponin in diagnosing AMI (5%)
Adachi et al¹³⁴	miRNA499	Human plasma	Increased in AMI patients in comparison to congestive HF
Olivieri et al¹³⁵	miRNA499-5p	Human plasma	This can be correlated better with AMI with no ST elevation as compared to troponin in aged AMI patients
Hoekstra et al¹³⁶	miRNA147	PBMCs	4 fold downregulated in CAD compared to control
Cheng et al¹³⁷	miRNA1	Human plasma	200 fold higher in patients with AMI at 6 h of the onset of symptoms and returned to normal levels after three days of the initial date of the symptoms
Ai et al¹³⁸	miRNA1	Human plasma	Significantly increased in AMI patients compared to atherosclerosis without AMI or healthy controls
D’Alessandra et al¹³⁹	miRNA133	Human and Mice plasma	Significantly upregulated in human AMI subjects and AMI animal models
Widera et al¹⁴⁰	miRNA1, miRNA133a	Human plasma	Significantly increased in AMI patients as compared to patients with unstable angina or any other coronary heart disease

Long non-coding RNA (lncRNA)

In 2002, Okazaki and his team first identified the long non-coding RNAs (>200 bp) while performing a wide range sequencing in a mouse model.¹³⁹ Subsequent studies found that long non-coding RNA (lncRNA) can be expressed in the cytoplasm or nucleus. The high stability of lncRNAs makes them interesting entities and an essential candidate for research. These long non coding RNAs may exist in extracellular fluids (ECF) like plasma with ultra-stability exhibiting a complex behavior on different disease states.^140-142 These RNAs are packed in exosomes/extracellular vesicles and can reach to the bloodstream when it released from the dying or apoptotic cells.^143,144 Packaging of lncRNAs into exosomes increases their stability and half-life. In addition, these large RNAs are found to be more stable when they linked to RNA binding proteins keeping them resistant against RNases. Due to the longer half-life and tremendously increased stability of lncRNAs make them easily detectible entities and hence may act as suitable and novel non-invasive diagnostic and prognostic biomarkers.

Like miRNAs, lncRNAs also do not encode protein though they exhibit similar structures like mRNA.¹⁴⁵ The ncRNAs play a crucial role in gene regulation processes and epigenetic changes.^146,147 The Long intergenic non-coding RNAs (lincRNAs) have been reported to play significant roles in a number of diseases, including coronary atherosclerosis,¹⁴⁸ immune disease,¹⁴⁹ and different type of malignancies.¹⁵⁰ Over the years, many experimental findings have demonstrated that lincRNAs have significant roles in the pathogenesis of cardiovascular disease.^151-153 Subsequently, the alterations in specific lncRNA are being proposed to be used as novel diagnostic and prognostic biomarkers of coronary atherosclerosis.^154-156 A large-scale single nucleotide polymorphism (SNP) association study conducted in the Japanese population found a long non-coding myocardial infarction association transcript (MIAT). They elucidated 6 SNPs in the MIAT that were statistically increased in patients of AMI.¹⁵⁷ In 2017 Qui and colleagues performed in vivo experiment and described MIAT as pro-fibrotic lncRNA in AMI.¹⁵⁸ Recent studies conducted in different in vitro and vivo model demonstrated that, the long nc RNA named super enhancer associated RNA called Wisper (Wisp2) has been widely expressed in cardiac fibroblast (CF).They also observed that Whisper was significantly overexpressed in mice with AMI.¹⁵⁹ Subsequent reports have shown that lncRNAs play a significant role in apoptotic cell death in patients with AMI, viz lncRNAs cardiac apoptosis-related lncRNA (Carl), and mitochondrial dynamic related lncRNA (Mdrl) were down-regulated AMI.^160,161

The lncRNA called long intergenic non-coding RNA predicting cardiac remodeling (LIPCAR) is significantly associated with the remodeling of left ventricular (LV) in patients of AMI, which leads to heart failure.¹⁶² They demonstrated that circulating LIPCAR levels were higher in AMI patients with repeated heart failure. Moreover, the LIPCAR was also found to be significantly associated with chronic heart failure patients with a severe coronary atherosclerosis condition. The plasma levels of LIPCAR was recognized as an important risk predictor for diastolic dysfunction in patients with type 2 diabetes.¹⁶³ It is also reported that circulating lncRNA, LIPCAR, and H19 were significantly associated with CAD and increased risk of chronic heart failure.^164,165 In 2017, another study showed that raised levels of circulating ANRIL was significantly associated with stent restenosis.¹⁶⁴ Therefore, detecting lncRNA in extracellular body fluids can be used as a prognostic and diagnostic biomarker repository for the pathology of coronary atherosclerosis and other diseases.^142,167

Circular RNA (circRNA)

Circular RNAs (circRNAs) are an addition to the advanced group of non-coding RNAs with an exciting finding in molecular research.¹⁶⁸ These circRNA are produced by the event of back-splicing method with a ring structure lacking 5′ cap and 3′ tail, which makes them more stable against RNAse degradation compared to linear nc RNA such as mRNA, miRNA, lncRNA etc. In the year of 1970s, scientists have first discovered circRNA in RNA viruses by the help of electron microscope.¹⁶⁹ Till the development of high throughput RNA sequencing circRNAs were considered as junk RNAs for last 2 decade.¹⁷⁰

Circular RNAs have added the worth of non-coding RNAs as a biomarker.¹⁷¹ Though the research about circRNAs is in its infancy, it has a role in various diseases. Studies have shown that circRNAs are significantly associated with Coronary Artery Disease. They are found ubiquitously in the eukaryotic world, most predominantly in the cytoplasm. Circular RNAs are found in different kind of species, comprising fungi, archaea, plants, insects, fish, and mammals.^170,172

Circular RNAs have been designated to have multiple roles such as regulator of transcription and translation, splicing participants, protein binding, miRNA sponges, etc.¹⁷⁰ Also, some circRNAs have been reported in protein synthesis using the cap-independent translational mechanism.¹⁶⁹ They exhibit a tissue-specific and developmental stage-specific pattern and serve as gene expression regulators in mammalian cells. Moreover, circRNAs have been reported to play diverse roles in the initiation and progression of neurological disorders, atherosclerotic disease risk, and a variety of cancers.¹⁷³

Table 5.

List of circRNA associated with coronary artery disease.

Reference	Sample source	Sample size	Methods	Type of circRNA	Expression pattern
Zhao et al¹⁷⁶	Blood	Discovery (case n = 12, control n = 12)	Microarray Real-time q PCR	Hsa_circ0124644	Upregulation
Zhao et al¹⁷⁶	Blood	Validation (cases n = 115, control n = 137)	Microarray Real-time q PCR	Hsa_circ0098964
Vausort et al¹⁷⁷	Blood	Cases (n = 642)	Real time q PCR	MIRCA	Down
Li et al¹⁷⁸	Blood	(cases CAD = 6, T2DM = 6 CAD + T2DM = 6 CONTROL = 20)	Microarray Real time q PCR	Hsa_circ11783	Downregulation
Vilades et al¹⁷⁹	Plasma	(n = 200)	Real time q PCR	Hsa_circ000145	Down

The research reports that have implicated the potential role of circRNAs in the initiation, development, and progression of Coronary artery disease are shown in Table 5. Most importantly, circRNAs have been found to be indispensable participants in the occurrence and progression of CAD.

Here we summarized the recent studies related to the discovery and effect of circRNAs in CAD pathogenesis (Table 5) and discussed some of research articles commenting on the feasibility of circRNAs to serve as biomarkers for cardiovascular diseases.

circRNAs as miRNA Sponge in Coronary Artery Disease

Studies on circRNAs have evidence that some of these RNA species exert their control in the expression of a specific gene through miRNA sponging effect. Due to the interaction with RNA binding proteins, circRNAs are involved in disease progression in CAD and are summarized in Table 6.

Table 6.

circRNA with targeted miRNA in CAD.

Reference	CircRNA	Target miRNA	Function
Lee et al¹⁸⁰	CDR1as	miR-7a	Overexpression of Poly (ADP-ribose) polymerase (PARP) and specificity protein 1 (SP1) acts as a miRNA sponge leads to apoptosis
Wang et al¹⁸¹	Mitochondrial Fission and apoptosis-related circRNA MFACR	miRNA-652-3p	Upregulation of apoptosis and mitochondrial fission
Wang et al¹⁸²	circ-081881	miRNA-548	Regulates PRPyI
Zhou and Yu¹⁸³	circRNA-010567	miRNA-141	Mediate fibrosis-associated protein resection

Epigenetic Biomarkers of CAD

Epigenetic biomarker defines any epigenetic mechanism which exposes the information about pathology of disease, detection of disease, predicts the risk of the disease development in future, predicts the significance of the disease, monitors to medication and therapy.¹⁸² Many epigenetics biomarkers have been reported for CAD and its progression.^183,184 Epigenetic modifications can present in both the form of covalent modifications in DNA/ Histone and pattern nc RNA expressions. Evidence suggests that candidate gene methylation patterns can serve as a potential epigenetic biomarker for diagnosis and prognosis of CAD (Table 2). The role of miRNAs in coronary artery disease has been widely studied over the years. Therefore, miRNAs are found to be major regulators in cellular gene expression for the initiation and progression of CAD. As discussed above altered levels of different circulating miRNAs could be used as diagnostic and prognostic markers of CAD (Table 4). Moreover, lncRNAs (sec b) and circRNAs have been reported to be potential biomarkers of CAD (Table 5).

Epigenetic Diversity Among CAD Patients

In contrast to the conventional principle, 1 individual’s genome does not differ from another. Scientists have established by their extensive research work that abundant differences do exist in nature for an individual’s epigenome. Thus, epigenetic modifications come from the diversity of nature comprising environmental exposure and pollutants, which lead to the development of deleterious diseases like CAD. Keeping this in consideration, scientists and physicians are trying to evolve novel therapeutic strategies based on these differences.¹⁸⁵ Furnishing the Human Genome project is the keystone of the inherent blueprint and backbone of genomics.^186,187 Within a decade of declaring the human genome project, researchers have reached to next-generation technology to understand the mechanism behind structural DNA to crucial activities in genome biology. With the advent of next-generation sequencing, scientists have been able to understand the role played by candidate genes and alterations in their nucleotide sequence towards the development of different diseases. Despite these approaches, the epigenetic world remains unexplored about precision medicine in CAD as of now. Worldwide researchers have already initiated efforts to comprehend epigenomics related to coronary artery disease.^188-190

Nowadays, several epigenome-based techniques have come up to explore the epigenetics related to CAD (Figure 4).

Figure 4.

Epigenetic modifications and techniques involved with different kind of sample sources: WGBS, whole-genome bisulfite sequencing; MSRE, methylation-sensitive restriction enzymes; HPLC, high-performance liquid chromatography; RRBS, reduced representation bisulfite sequencing; ONT, Oxford nanopore technologies; Pyrosequencing—attractive alternative to the conventional bisulfite sequencing PCR (BSP); HRM assay; RT-PCR based high resolution melting curve analysis; ChIP, chromatin immunoprecipitation; MS, mass spectrometry; microarray; RNA seq, RNA sequencing.

Epigenetic Therapeutic Targets in CAD

The veracity of altered environmental exposure could be an epigenetic marker for upcoming treatment. According to researchers, these modifications can be inverted using pharmaceutical agents and nutraceuticals. For example, DNA methyltransferase inhibitors (DNMTis), histone acetyltransferase inhibitors, histone deacetylase inhibitors, histone methylase inhibitors, and bromodomain and extra terminal motif (BET) inhibitors have been extensively studied as conceivable therapeutics in inflammation and CAD.¹⁹¹ Although DNMTs are present in various food items naturally, many synthetic man-made ones are being used widely as well.¹⁹²

Epigenetics Toward Personalized Medicine

Since the remote past, our health care professionals have been striving to offer the best care and effective treatment to their patients, as already discussed above. They have been doing this by experimenting with different treatment strategies, selecting the better successful ones based on their observational analysis, sharing their inferences with an expectation of improving the strategy of their predecessors. The ultimate goal of the efforts was to provide more accurate, precise, and effective treatment for each individual no matter how necessary the tools were at their disposal. However, nowadays, the advent of modern innovative techniques of genetic testing, data analysis, supercomputing devices, and electronic data storage has enabled physicians and scientists to take the area of precision medicine to a level which their historical predecessors could not even think of.

Precision medicine can take the management of a disease to its ultimate goal, i.e., complete cure of the disease. For example, Alexis and Noah, the famous twins who were misdiagnosed and mistreated, for about 14 years, for a condition called palsy. They received the treatment for palsy until human genome sequencing, and DNA sequencing made it possible to correctly diagnose their actual disease condition, that is, dystonia.¹⁹³ The sequencing of the human genome took an international collaboration of 13 years and amounted to a financial costing of US$3 billion. However, the advancement in techniques involved, human genome sequencing, can be completed in 24 hours for just US$1000. This has made us capable of tailoring the prevention to an individual patient or group of patients using their genomic information in combination with their environment and lifestyles.

Although human genome sequencing has opened up the window for the interesting discipline of genetic medicine, which then leads the path to develop personalized medicine, it has become clear now, after 17 years, that our genetic material (genes) alone is not able to thoroughly explain the fundamental aspects of development and aging. Moreover, our genes are not enough to predict our susceptibility to different types of diseases. Epigenetics has already answered a lot of curiosity questions that bothered physicians and scientists for a large amount of time in the past. Epigenetics and factors affecting epigenetics mechanisms are attracting the attention of researchers and are being used to elucidate the underlying causes of the onset and progression of numerous life-threatening diseases. Innovative techniques that are harnessed to study epigenetics and epigenetic mechanisms are revolutionizing the approaches to personalized medicine (Figure 4). Innovative technologies to study epigenetics, such as bisulfite sequencing, have the ability to accurately quantify and map epigenetic marks underlying the causation of a particular disease phenotype, including CAD. This was not possible using traditionally used genetic research techniques. Epigenetic modifications determine the cell identity and make a skin cell different from a liver cell or heart cell. In many disease phenotypes like cardiac diseases, neurological diseases, or cancer, epigenetic changes are much more frequent than genetic variants, therefore, providing more vital insights into understanding the development and progression of these disease phenotypes.

Accurate mapping and quantitation of epigenetic markers help us in improving clinical practices and approaches by improving the diagnosis of diseases at the early stages of disease development, even prior to the happening of genetic changes.¹⁹⁴ Research reports are demonstrating that epigenetic variations precede frequent genetic alterations in disease development.¹⁹⁵ Therefore, detection of early disease signals by exploiting epigenetic based diagnostics offers opportunities for clinical intervention even before the appearance or progression of symptoms impact life quality when the patient is relatively fit. This favors our treatment process and success to treat the condition even before it appears. In this way, management of disease and prognosis is performed in more accurate manner.^196-198

The concept of personalization of medicine in the context of coronary atherosclerosis could take the management of CAD to even more refinement than other diseases. Environmental factors are potential influencers of CADs. These environmental factors induce epigenetic changes, which in turn affect the genetic expression of an individual in the course of disease development. Therefore, taken together, the characterization of epigenetic aberrations in CAD precision medicine requires careful consideration.

Conclusion

This review summarized recent findings linked to epigenetic study in CAD and illustrated the impact of the epigenetic mechanism in CAD. Epigenetics has significantly influenced our understanding of gene regulation in CAD, although consensus regarding the magnitude of effect size is lacking. Epigenome intensely responds to variations in the environment during an individual’s lifetime contributions in the regulation of critical biological mechanisms and provides a significant association among life experiences, phenotypic expression, and risk of disease development. Since environmental inducements associated with epigenetics are inconsistent with the ethnicity of the population, results are difficult to generalize, and regional studies are imperative. Epigenetic aspects of in-utero exposure and after birth exposure, like dietary factors, have been inadequately explored. Future strategy for further research must incorporate elucidation of diagnostic biomarker potential and therapeutic targets for atherosclerotic disorders in order to translate emerging epigenetic data in bedside care. Moreover, with the help of epigenetics and techniques to study epigenetic factors, the present-day physician and researchers could take personalized medicine to a level unreachable to their ancestors.

Footnotes

Acknowledgements

Facilities provided by Govind Ballabh Pant Postgraduate Institute of Medical Education and Research (GIPMER), New Delhi, are acknowledged. Authors are grateful to the Department of Biotechnology Government of India for financial support provided under the head of “Establishment of Central Molecular Lab in GIPMER to study the diagnosis for precision medicine in order to understand the disease process and utilize it as Clinical Research Facility” with Grant No. BT/INF/22/SP33063/2019.

Funding:

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is funded by the Department of Biotechnology (DBT), Govt. of India, India (BT/INF/22/SP33063/2019).

Declaration of conflicting interests:

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Author Contributions

MPS and BM were involved in planning, designing the manuscript. MPS was involved in the writing of the manuscript. RSAS, N, A, AK, AKS, EA, and AA were involved in reviewing the manuscript. Finally, the manuscript was approved by BM and SSS.

List of Abbreviation

CAD: Coronary Artery Disease

AMI: Acute Myocardial Infarction

DM: Diabetes Mellitus

VSMCs: Vascular Smooth Muscle Cells

ECs: Endothelial Cells

SHS: Second Hand Smoke

DASH: Dietary Approaches to Stop Hypertension

DNMTs: DNA methyltransferases

IGF2: Insulin Like Growth Factor-2

IR: Insulin Receptor

ABCG1: ATP Binding Cassette Subfamily G Member

CPTIA: Carnitine palmitoyl transferase 1A

HPLC: High Performance Liquid Chromatography

MSRE: Methylation-Sensitive Restriction Enzymes

LDL: Low Density Lipoprotein

MS PCR: Methylation-specific Polymerase Chain Reaction

MS-HRM: Methylation Specific High Resolution Melting Curve

EWAS: Epigenome-Wide Association Studies

KMT: Lysine Methyltransferase

KDM: Lysine De-Methylase

SAM: S-adenosylmethionine

LSDs: Lysine-specific de-methylases

EZH2: Equivalent Histone Methyltransferase

KATs: Lysine Acetyltransferase initially

HATs: Histone Acetyltransferase

HDACs: Histone Deacetylases

ex-LDL: Oxidized Low-Density Lipoprotein

CAMII δ: Calcium/ calmodulin-Dependent Protein Kinase II δ

nc RNAs: non-coding RNAs

miRNAs: micro RNAs

lncRNA: Long non-coding RNA

ECF: Extracellular Fluids

SNP: Single Nucleotide Polymorphism

MIAT: Myocardial Infarction Association Transcript

LIPCAR: Long Intergenic non-coding RNA Predicting Cardiac Remodelling

ANRIL:

circRNA: circular RNA

WGBS: Whole Genome Bisulphite Sequencing,

RRBS: Reduced Representation Bisulphite Sequencing,

ONT: Oxford Nanopore Technologies

ChIP: Chromatin immunoprecipitation,

MS: Mass Spectrometry

RNA seq: RNA sequencing

DNMTis: DNA methyltransferase inhibitors

References

Liu

C-F

Tang

WHW

. Epigenetics in cardiac hypertrophy and heart failure. JACC Basic Transl Sci. 2019;4:976–993.

Roth

Johnson

Abajobir

, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1-25.

Majnik

Lane

RH.

Epigenetics: where environment, society and genetics meet. Epigenomics. 2014;6:1-4.

Grimaldi

Vietri

Schiano

, et al. Epigenetic reprogramming in atherosclerosis. Curr Atheroscler Rep. 2015;17:476.

Ross

The pathogenesis of atherosclerosis—an update. N Engl J Med. 1986;314:488-500.

Ross

Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340:115-126.

Sayols-Baixeras

Lluís-Ganella

Lucas

Elosua

Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl Clin Genet. 2014;7:15.

Sanchis-Gomar

Perez-Quilis

Leischik

Lucia

Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4:256.

Varma

Kundan

Ananthanarayanan

, et al. Demographic profile, clinical characteristics and outcomes of patients undergoing coronary artery bypass grafting—retrospective analysis of 4,024 patients. Indian J Thorac Cardiovasc Surg. 2014;30:272-277.

10.

Dhingra

Vasan

RS.

Age as a risk factor. Med Clin North Am. 2012;96:87-91. doi:10.1016/j.mcna.2011.11.003

11.

Rossi

Grimaldi

Origliani

Fantini

Coppi

Modena

MG.

Menopause and cardiovascular risk. Pathophysiol Haemost Thromb. 2002;32:325-328.

12.

Maas

Appelman

YE.

Gender differences in coronary heart disease. Neth Heart J. 2010;18:598-602.

13.

Grady

Chaput

Kristof

Results of Systematic Review of Research on Diagnosis and Treatment of Coronary Heart Disease in Women: Summary. InAHRQ Evidence Report Summaries; 2003. Agency for Healthcare Research and Quality (US).

14.

Mosca

Barrett-Connor

Wenger

NK.

Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011;124:2145-2154. doi:10.1161/CIRCULATIONAHA.110.968792ss

15.

Smail

HO.

The epigenetics of diabetes, obesity, overweight and cardiovascular disease. AIMS Genetics. 2019;6:36-45. doi:10.3934/genet.2019.3.36

16.

Gallardo-Escribano

Buonaiuto

Ruiz-Moreno

, et al. Epigenetic approach in obesity: DNA methylation in a prepubertal population which underwent a lifestyle modification. Clin Epigenetics. 2020;12:144.

17.

Siemelink

van der Laan

Haitjema

, et al. Smoking is associated to DNA methylation in atherosclerotic carotid lesions. Circ Genom Precis Med. 2018;11:e002030.

18.

Steenaard

Ligthart

Stolk

, et al. Tobacco smoking is associated with methylation of genes related to coronary artery disease. Clin Epigenetics. 2015;7:54.

19.

Athyros

Katsiki

Doumas

Karagiannis

Mikhailidis

DP.

Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin. 2013;29:1263-1274.

20.

Lohoff

Sorcher

Rosen

, et al. Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder. Mol Psychiatry. 2018;23:1900-1910.

21.

Mendler

Braun

Müller

The ubiquitin-like SUMO system and heart function: from development to disease. Circ Res. 2016;118:132-144.

22.

Barker

DJ.

Early growth and cardiovascular disease. Arch Dis Child.1999;80:305-307.

23.

Barker

Winter

Osmond

Margetts

Simmonds

SJ.

Weight in infancy and death from ischaemic heart disease. Lancet. 1989;2:577-580.

24.

Agarwal

Morriseau

Kereliuk

Doucette

Wicklow

Dolinsky

VW.

Maternal obesity, diabetes during pregnancy and epigenetic mechanisms that influence the developmental origins of cardiometabolic disease in the offspring. Crit Rev Clin Lab Sci. 2018;55:71-101.

25.

Ordovás

Smith

Epigenetics and cardiovascular disease. Nat Rev Cardiol. 2010;7:510-519.

26.

Bhatnagar

Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ Res. 2006;29;99:692-705.

27.

Joehanes

Just

Marioni

, et al. Epigenetic signatures of cigarette smoking. Circ Cardiovasc Genet. 2016;9:436-447.

28.

Mozaffarian

Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation. 2016;133:187-225.

29.

Zhang

Kutateladze

TG.

Diet and the epigenome. Nat Commun. 2018;9:3375.

30.

Alegría-Torres

Baccarelli

Bollati

Epigenetics and lifestyle. Epigenomics. 2011;3:267-277.

31.

Phillips

NLH

Roth

TL.

Animal models and their contribution to our understanding of the relationship between environments, epigenetic modifications, and behavior. Genes (Basel). 2019;10:47.

32.

Horii

Morita

Hino

, et al. Successful generation of epigenetic disease model mice by targeted demethylation of the epigenome. Genome Biol. 2020;21:77.

33.

Bennett

AJ.

Gene environment interplay: nonhuman primate models in the study of resilience and vulnerability. Dev Psychobiol. 2008;50:48-59.

34.

Rosenfeld

CS.

Animal models to study environmental epigenetics. Biol Reprod. 2010;82:473-488.

35.

Lloyd

Robinson

MacRae

CA.

Animal-based studies will be essential for precision medicine. Sci Transl Med. 2016;8:352ed12.

36.

Duan

Liu

Wang

Liao

The dynamic changes of DNA methylation in primordial germ cell differentiation. Gene. 2016;591:305-312.

37.

Smith

Chan

Mikkelsen

, et al. A unique regulatory phase of DNA methylation in the early mammalian embryo. Nature. 2012;484:339-344.

38.

Wong

Chim

CS.

DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics. 2011;3:83-92.

39.

Baccarelli

Ghosh

Environmental exposures, epigenetics and cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2012;15:323-329.

40.

Weber

Hellmann

Stadler

, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007;39:457-466.

41.

Chaudhary

Nakka

Maulik

Chattopadhyay

Epigenetic manifestation of metabolic syndrome and dietary management. Antioxid Redox Signal. 2012;17:254-281.

42.

Lewitt

Dent

Hall

The insulin-like growth factor system in obesity, insulin resistance and type 2 diabetes mellitus. Journal of clinical medicine. 2014,3:1561-74.

43.

Hardy

Frisdal

Le Goff

Critical role of the human ATP-binding cassette G1 transporter in cardiometabolic diseases. Int J Mol Sci. 2017;18:1892.

44.

Frazier-Wood

Aslibekyan

Absher

, et al. Methylation at CPT1A locus is associated with lipoprotein subfraction profiles. J Lipid Res. 2014;55:1324-1330.

45.

Hai

Zuo

Aberrant DNA methylation in the pathogenesis of atherosclerosis. Clinica Chim Acta. 2016;456:69-74.

46.

Zhong

Agha

Baccarelli

AA.

The role of DNA methylation in cardiovascular risk and disease. Circ Res. 2016;118:119-131.

47.

Kalhan

SC.

One carbon metabolism in pregnancy: impact on maternal, fetal and neonatal health. Mol Cell Endocrinol. 2016;5;435:48-60.

48.

Erdman

Jr Balentine

Arab

, et al. Flavonoids and Heart Health: proceedings of the ILSI North America flavonoids workshop, May 31–June 1, 2005, Washington, DC. J Nutr. 2007;137(suppl 1):718S-737S.

49.

Sabogal

Tingen

Kapuku

Wang

Cigarette smoking related DNA methylation in peripheral leukocytes and cardiovascular risk in young adults. Int J Cardiol. 2020;306:203-205.

50.

Baccarelli

Rienstra

Benjamin

EJ.

Cardiovascular epigenetics: basic concepts and results from animal and human studies. Circ Cardiovasc Genet. 2010;3:567-573.

51.

Turunen

Aavik

Yla-Herttuala

Epigenetics and atherosclerosis. Biochim Biophys Acta. 2009;1790:886-891.

52.

Makar

Wilson

CB.

DNA methylation is a nonredundant repressor of the Th2 effector program. J Immunol. 2004;173:4402-4406.

53.

Chen

Karaplis

Ackerman

, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet. 2001;10:433-443.

54.

Lund

Andersson

Lauria

, et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem. 2004;279:29147-29154.

55.

Baccarelli

Wright

Bollati

, et al. Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology. 2010;21:819-828.

56.

Kim

Long

Arakawa

Wang

Mimi

Laird

PW.

DNA methylation as a biomarker for cardiovascular disease risk. PLoS One. 2010;5:e9692.

57.

Zaina

Heyn

Carmona

, et al. DNA methylation map of human atherosclerosis. Circ Cardiovasc Genet. 2014;7:692-700.

58.

Nazarenko

Markov

Sleptcov

, et al. Genome-wide profiling of DNA methylation in human atherosclerotic plaques. Atherosclerosis. 2015;241:e84-e85.

59.

del Pilar Valencia-Morales

Zaina

Heyn

, et al. The DNA methylation drift of the atherosclerotic aorta increases with lesion progression. BMC Med Genomics. 2015;8:7.

60.

Hiltunen

Turunen

Häkkinen

, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 2002;7:5-11.

61.

Sharma

Garg

Kumar

, et al. Genome wide DNA methylation profiling for epigenetic alteration in coronary artery disease patients. Gene. 2014;541:31-40.

62.

Sharma

Kumar

Garg

, et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol. 2008;27:357-365.

63.

Zhu

Goldschmidt-Clermont

Dong

Inactivation of monocarboxylate transporter MCT3 by DNA methylation in atherosclerosis. Circulation. 2005;112:1353-1361.

64.

Huang

Y-S

Zhi

Y-F

Wang

S-R.

Hypermethylation of estrogen receptor-alpha gene in atheromatosis patients and its correlation with homocysteine. Pathophysiology. 2009;16:259-265.

65.

Kim

Song

, et al. Epigenetic changes in estrogen receptor β gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta. 2007;1772:72-80.

66.

Zuo

H-P

Guo

Y-Y

Che

X-Z.

Hypomethylation of interleukin-6 promoter is associated with the risk of coronary heart disease. Arq Bras Cardiol. 2016;107:131-136.

67.

Bakshi

Vijayvergiya

Dhawan

Aberrant DNA methylation of M1-macrophage genes in coronary artery disease. Sci Rep. 2019;9:1429.

68.

Ghose

Ghosh

Tanwar

, et al. Investigating coronary artery disease methylome through targeted bisulfite sequencing. Gene. 2019;721:144107.

69.

Nakatochi

Ichihara

Yamamoto

, et al. Epigenome-wide association of myocardial infarction with DNA methylation sites at loci related to cardiovascular disease. Clin Epigenetics. 2017;9:54.

70.

Rask-Andersen

Martinsson

Ahsan

, et al. Epigenome-wide association study reveals differential DNA methylation in individuals with a history of myocardial infarction. Hum Mol Genet. 2016;25:4739-4748.

71.

Fernández-Sanlés

Sayols-Baixeras

Subirana

Degano

Elosua

Association between DNA methylation and coronary heart disease or other atherosclerotic events: a systematic review. Atherosclerosis. 2017;263:325-333.

72.

Michels

Binder

Dedeurwaerder

, et al. Recommendations for the design and analysis of epigenome-wide association studies. Nat Methods. 2013;10:949-955.

73.

Castillo-Díaz

Garay-Sevilla

Hernández-González

Solís-Martínez

Zaina

Extensive demethylation of normally hypermethylated CpG islands occurs in human atherosclerotic arteries. Int J Mol Med. 2010;26:691-700.

74.

Yamada

Horibe

Oguri

, et al. Identification of novel hyper- or hypomethylated CpG sites and genes associated with atherosclerotic plaque using an epigenome-wide association study. Int J Mol Med. 2018;41:2724-2732.

75.

Shen

Peng

Bai

, et al. Epigenome-Wide Association Study Indicates Hypomethylation of MTRNR2L8 in Large-Artery Atherosclerosis Stroke. Stroke. 2019;50:1330-1338.

76.

Banerjee

Ponde

Rajani

Ashavaid

TF.

Differential methylation pattern in patients with coronary artery disease: pilot study. Mol Biol Rep. 2019;46:541-550.

77.

Draizen

Shaytan

Mariño-Ramírez

Talbert

Landsman

Panchenko

AR.

HistoneDB 2.0: a histone database with variants–an integrated resource to explore histones and their variants. Database (Oxford). 2016;2016:baw014.

78.

Berger

SL.

The complex language of chromatin regulation during transcription. Nature. 2007;447:407-412.

79.

Natsume-Kitatani

Shiga

Mamitsuka

Genome-wide integration on transcription factors, histone acetylation and gene expression reveals genes co-regulated by histone modification patterns. PLoS One. 2011;6:e22281.

80.

Jenuwein

Allis

CD.

Translating the histone code. Science. 2001;293:1074.

81.

Wei

Zhu

X-H

Jiang

D-S.

Histone methylation and vascular biology. Clin Epigenetics. 2020;12:30.

82.

Rothbart

Strahl

BD.

Interpreting the language of histone and DNA modifications. Biochim Biophys Acta. 2014;1839:627-643.

83.

Rea

Eisenhaber

O’Carroll

, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 2000;406:593-599.

84.

Lachner

O’Sullivan

Jenuwein

An epigenetic road map for histone lysine methylation. J Cell Sci. 2003;116(Pt 11):2117-2124.

85.

Shi

Lan

Matson

, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941-953.

86.

Shi

Tsukada

The discovery of histone demethylases. Cold Spring Harb Perspect Biol. 2013;5:a017947 .

87.

Wolf

SS.

The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans. Cell Mol Life Sci. 2009;66:2109-2121.

88.

Lee

Wynder

Cooch

Shiekhattar

An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature. 2005;437:432-435.

89.

Tsukada

Fang

Erdjument-Bromage

, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439:811-816.

90.

Chang

Chen

Zhao

Bruick

RK.

JMJD6 is a histone arginine demethylase. Science. 2007;318:444-447.

91.

Greißel

Culmes

Napieralski

, et al. Alternation of histone and DNA methylation in human atherosclerotic carotid plaques. Thromb Haemost. 2015;114:390-402.

92.

Greißel

Culmes

Burgkart

, et al. Histone acetylation and methylation significantly change with severity of atherosclerosis in human carotid plaques. Cardiovasc Pathol. 2016;25:79-86.

93.

Phillips

DM.

The presence of acetyl groups of histones. Biochem J. 1963;87:258-263.

94.

Allfrey

Pogo

Littau

Gershey

Mirsky

AE.

Histone acetylation in insect chromosomes. Science. 1968;159:314-316.

95.

Yang

X-J

Seto

Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell. 2008;31:449-461.

96.

Blander

Guarente

The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004;73:417-435.

97.

Cheung

Briggs

Allis

CD.

Acetylation and chromosomal functions. Curr Opin Cell Biol. 2000;12:326-333.

98.

Yang

X-J

Seto

HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26:5310-5318.

99.

Bannister

Kouzarides

Regulation of chromatin by histone modifications. Cell Res. 2011;21:381-395.

100.

Pandey

Sikka

Bergman

, et al. Transcriptional regulation of endothelial arginase 2 by histone deacetylase 2. Arterioscler Thromb Vasc Biol. 2014;34:1556-1566.

101.

Oki

Aihara

Ito

Role of histone phosphorylation in chromatin dynamics and its implications in diseases. Subcell Biochem. 2007;41:319-336.

102.

Backs

Neef

, et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A. 2009;106:2342-2347.

103.

Awad

Al-Haffar

KMA

Marashly

, et al. Control of histone H3 phosphorylation by CaMKIIδ in response to haemodynamic cardiac stress. J Pathol. 2015;235:606-618.

104.

Awad

Kunhi

Little

, et al. Nuclear CaMKII enhances histone H3 phosphorylation and remodels chromatin during cardiac hypertrophy. Nucleic Acids Res. 2013;41:7656-7672.

105.

Song

Luo

Z-Q.

Post-translational regulation of ubiquitin signaling. J Cell Biol. 2019;218:1776-1786.

106.

Wang

Schwartz

RJ.

Sumoylation and regulation of cardiac gene expression. Circ Res. 2010;107:19-29.

107.

Han

Z-J

Feng

Y-H

B-H

Y-M

Chen

The post-translational modification, SUMOylation, and cancer (Review). Int J Oncol. 2018;52:1081-1094.

108.

Kang

Zuo

, et al. SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell. 2010;38:191-201.

109.

X-C

Zeng

Sun

R-R

Liu

Chen

Zhang

P-Y.

SUMOylation in cardiac disorders - a review. Eur Rev Med Pharmacol Sci. 2017;21:1583-1587.

110.

Yang

Wang

, et al. Protein SUMOylation modification and its associations with disease. Open Biol. 2017;7:170167.

111.

ENCODE Project Consortium. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science. 2004;306:636-640.

112.

Bertone

Stolc

Royce

, et al. Global identification of human transcribed sequences with genome tiling arrays. Science. 2004;306:2242-2246.

113.

Hangauer

Vaughn

McManus

MT.

Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet. 2013;9:e1003569.

114.

Kung

JTY

Colognori

Lee

. Long noncoding RNAs: past, present, and future. Genetics. 2013;193:651-669.

115.

Thomas

CA.

The genetic organization of chromosomes. Annu Rev Genet. 1971;5:237-256.

116.

Mirsky

Ris

The desoxyribonucleic acid content of animal cells and its evolutionary significance. J Gen Physiol. 1951;34:451-462.

117.

Poller

Dimmeler

Heymans

, et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J. 2018;39:2704-2716.

118.

Boon

Jaé

Holdt

Dimmeler

Long noncoding RNAs: from clinical genetics to therapeutic targets?

J Am Coll Cardiol. 2016;67:1214-1226.

119.

Friedman

Farh

KK-H

Burge

Bartel

DP.

Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92-105.

120.

Zhang

Liu

Meyer

, et al. Model-based Analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.

121.

Abi Khalil

. The emerging role of epigenetics in cardiovascular disease. Ther Adv Chronic Dis. 2014;5:178-187.

122.

Fichtlscherer

De Rosa

Fox

, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107:677-684.

123.

Vindis

Faccini

Ruidavets

, et al. Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease. Atherosclerosis. 2017;263:e277.

124.

Wang

Long

Zhao

, et al. Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis. J Transl Med. 2013;11:222.

125.

Liu

Yang

Fei

, et al. Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease. Biomed Rep. 2016;5:332-336.

126.

Zhang

H-H

Yang

B-J

Gao

Z-Y.

Association between circulating microRNA-208a and severity of coronary heart disease. Scand J Clin Lab Invest. 2017;77:379-384.

127.

Wang

Yan

C-H

, et al. MicroRNA-31 controls phenotypic modulation of human vascular smooth muscle cells by regulating its target gene cellular repressor of E1A-stimulated genes. Exp Cell Res. 2013;319:1165-1175.

128.

Sayed

ASM

Xia

Yang

T-L

Peng

. Circulating microRNAs: a potential role in diagnosis and prognosis of acute myocardial infarction. Dis Markers. 2013;35:561-566.

129.

Sondermeijer

Bakker

Halliani

, et al. Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624. PLoS One. 2011;6:e25946.

130.

Corsten

Dennert

Jochems

, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3:499-506.

131.

Xin

Yang

Han

Circulating miR-499 as a potential biomarker for acute myocardial infarction. Ann Transl Med. 2016;4:135.

132.

Adachi

Nakanishi

Otsuka

, et al. Plasma MicroRNA 499 as a biomarker of acute myocardial infarction. Clin Chem. 2010;56:1183-1185.

133.

Olivieri

Antonicelli

Lorenzi

, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol. 2013;167:531-536.

134.

Hoekstra

van der Lans

Halvorsen

, et al. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun. 2010;394:792-797.

135.

Cheng

Tan

Yang

, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci. 2010;119:87-95.

136.

Zhang

, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010;391:73-77.

137.

D’Alessandra

Devanna

Limana

, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010;31:2765-2773.

138.

Widera

Gupta

Lorenzen

, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51:872-875.

139.

Okazaki

Furuno

Kasukawa

, et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature. 2002;420:563-573.

140.

Zhou

Zhang

Jin

Chen

Kong

lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy. Cell Death Dis. 2017;8:e2929.

141.

Martignano

Rossi

Maugeri

, et al. Urinary RNA-based biomarkers for prostate cancer detection. Clinica Chimica Acta. 2017;473:96-105.

142.

Terracciano

Ferro

Terreri

, et al. Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. Transl Res. 2017;184:108-117.

143.

Shao

Zhang

, et al. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumor Biol. 2015;36:2007-2012.

144.

Viereck

Thum

Circulating Noncoding RNAs as biomarkers of cardiovascular disease and injury. Circ Res. 2017;120:381-399.

145.

Quinn

Chang

HY.

Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17:47-62.

146.

Laham-Karam

Laitinen

Turunen

Ylä-Herttuala

Activating the chromatin by noncoding RNAs. Antioxid Redox Signal. 2018;29:813-831.

147.

Butler

Webb

Lubin

FD.

Regulatory RNAs and control of epigenetic mechanisms: expectations for cognition and cognitive dysfunction. Epigenomics. 2016;8:135-151.

148.

Haemmig

Simion

Yang

Deng

Feinberg

MW.

Long noncoding RNAs in cardiovascular disease, diagnosis, and therapy. Curr Opin Cardiol. 2017;32:776-783.

149.

Mumtaz

Bhat

Ahmad

, et al. LncRNAs and immunity: watchdogs for host pathogen interactions. Biol Proced Online. 2017;19:1-2.

150.

Wang

, et al. LncRNAs in DNA damage response and repair in cancer cells. Acta Biochim Biophys Sin (Shanghai). 2018;50:433-439.

151.

Grote

Wittler

Hendrix

, et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev Cell. 2013;24:206-214.

152.

Lin

Wang

, et al. Let-7e modulates the inflammatory response in vascular endothelial cells through ceRNA crosstalk. Sci Rep. 2017;7:42498.

153.

Viereck

Kumarswamy

Foinquinos

, et al. Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med. 2016;8:326ra22.

154.

Ono

Kuwabara

Horie

Kimura

Long non-coding RNAs as key regulators of cardiovascular diseases. Circ J. 2018;82:1231-1236.

155.

Arslan

Berkan

Lalem

, et al. Long non-coding RNAs in the atherosclerotic plaque. Atherosclerosis. 2017;266:176-181.

156.

Zhu

Long noncoding RNA: recent updates in atherosclerosis. Int J Biol Sci. 2016;12:898-910.

157.

Ishii

Ozaki

Sato

, et al. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet. 2006;51:1087-1099.

158.

Shu

, et al. MIAT is a pro-fibrotic long non-coding RNA governing cardiac fibrosis in post-infarct myocardium. Sci Rep. 2017;7:42657.

159.

Micheletti

Plaisance

Abraham

, et al. The long noncoding RNA <em>Wisper</em> controls cardiac fibrosis and remodeling. Sci Transl Med. 2017;9:eaai9118.

160.

Wang

Long

Zhou

, et al. CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nat Commun. 2014;5:1-3.

161.

Wang

Zhang

, et al. The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat Med. 2016;22:1131-1139.

162.

Kumarswamy

Bauters

Volkmann

, et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res. 2014;114:1569-1575.

163.

de Gonzalo-Calvo

Kenneweg

Bang

, et al. Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes. Sci Rep. 2016;6:37354.

164.

Hobuß

Bär

Thum

Long non-coding RNAs: at the heart of cardiac dysfunction?

Front Physiol. 2019;10:30.

165.

Xuan

Sun

Zhang

, et al. Circulating long non-coding RNA s NRON and MHRT as novel predictive biomarkers of heart failure. J Cell Mol Med. 2017;21:1803-1814.

166.

Wang

Liu

Zhong

, et al. Long noncoding RNA ANRIL as a novel biomarker of lymph node metastasis and prognosis in human cancer: a meta-analysis. Oncotarget. 2017;9:14608-14618.

167.

Gutschner

Richtig

Haemmerle

Pichler

From biomarkers to therapeutic targets—the promises and perils of long non-coding RNAs in cancer. Cancer Metastasis Rev.2018;37:83-105.

168.

Haddad

Lorenzen

JM.

Biogenesis and function of circular RNAs in health and in disease. Front Pharmacol. 2019;10:428.

169.

Jeck

Sharpless

NE.

Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32:453-461.

170.

Memczak

Jens

Elefsinioti

, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333-338.

171.

Bayoumi

Aonuma

Teoh

Tang

Kim

Circular noncoding RNAs as potential therapies and circulating biomarkers for cardiovascular diseases. Acta Pharmacol Sin. 2018;39:1100-1109.

172.

Wang

Bao

Yee

M-C

, et al. Circular RNA is expressed across the eukaryotic tree of life. PLoS One. 2014;9:e90859.

173.

Lei

Tian

Fan

Circular RNA: a novel biomarker and therapeutic target for human cancers. Int J Med Sci. 2019;16:292-301.

174.

Zhao

Gao

, et al. Peripheral blood circular RNA hsa_circ_0124644 can be used as a diagnostic biomarker of coronary artery disease. Sci Rep. 2017;7:39918.

175.

Vausort

Salgado-Somoza

Zhang

, et al. Myocardial infarction-associated circular RNA predicting left ventricular dysfunction. J Am Coll Cardiol. 2016;68:1247-1248.

176.

Zhao

Jian

Tang

Hsa-circRNA11783-2 in peripheral blood is correlated with coronary artery disease and type 2 diabetes mellitus. Diab Vasc Dis Res. 2017;14:510-515.

177.

Vilades

Martínez-Camblor

Ferrero-Gregori

, et al. Plasma circular RNA hsa_circ_0001445 and coronary artery disease: performance as a biomarker. FASEB J. 2020;34:4403-4414.

178.

Lee

ECS

Elhassan

SAM

Lim

GPL

, et al. The roles of circular RNAs in human development and diseases. Biomed Pharmacother. 2019;111:198-208.

179.

Wang

Gan

T-Y

, et al. Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression. Cell Death Differ. 2017;24:1111-1120.

180.

Wang

Piao

, et al. Circular RNAs as potential biomarkers and therapeutics for cardiovascular disease. PeerJ. 2019;7:e6831.

181.

Zhou

JW.

A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-β1. Biochem Biophys Res Commun. 2017;487:769-775.

182.

García-Giménez

Seco-Cervera

Tollefsbol

, et al. Epigenetic biomarkers: current strategies and future challenges for their use in the clinical laboratory. Crit Rev Clin Lab Sci. 2017;54:529-550.

183.

Cardona-Monzonís

Beltrán-García

Ibañez-Cabellos

, et al. Epigenetic biomarkers in cardiovascular disease. J Lab Precis Med. 2018;3:24.

184.

Metzinger

de Franciscis

Serra

The management of cardiovascular risk through epigenetic biomarkers. BioMed Res Int. 2017;2017:9158572.

185.

Fox

Hall

Arnett

, et al. Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation. 2015;131:1715-1736.

186.

Lander

Linton

Birren

, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.

187.

International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931-945.

188.

Green

Guyer

National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470:204-213.

189.

Altman

Ashley

EA.

Using “big data” to dissect clinical heterogeneity. Circulation. 2015;131:232-233.

190.

Leopold

Loscalzo

Emerging role of precision medicine in cardiovascular disease. Circ Res. 2018;122:1302-1315.

191.

Nicorescu

Dallinga

de Winther

MPJ

Stroes

ESG

Bahjat

Potential epigenetic therapeutics for atherosclerosis treatment. Atherosclerosis. 2019;281:189-197.

192.

Chistiakov

Orekhov

Bobryshev

YV.

Treatment of cardiovascular pathology with epigenetically active agents: focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation. Int J Cardiol. 2017;227:66-82.

193.

Yang

YB.

The role of genetics in medicine: a future of precision medicine. Br Col Med J. 2019;61:388-399.

194.

Raiber

E-A

Beraldi

Martínez Cuesta

, et al. Base resolution maps reveal the importance of 5-hydroxymethylcytosine in a human glioblastoma. NPJ Genomic Med. 2017;2:6.

195.

Vaz

Hwang

Kagiampakis

, et al. Chronic cigarette smoke-induced epigenomic changes precede sensitization of bronchial epithelial cells to single-step transformation by KRAS mutations. Cancer Cell. 2017;32:360-376.e6.

196.

Van Neste

Groskopf

Grizzle

, et al. Epigenetic risk score improves prostate cancer risk assessment. Prostate. 2017;77:1259-1264.

197.

Joosten

Deckers

Aarts

, et al. Prognostic DNA methylation markers for renal cell carcinoma: a systematic review. Epigenomics. 2017;9:1243-1257.

198.

Koschmieder

Vetrie

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options. Semin Cancer Biol. 2017;51:180-197.